Now showing items 1-1 of 1
Preclinical evaluation of 177Lu-BBR2 antagonist radiothearpy of prostate cancer
(University of Missouri--Columbia, 2013)
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] Castration resistant prostate cancer (CRPC) is the second most common cause of cancer death in the United States. Current treatment protocols offer ...